LOESTRIN 21 1.5 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Loestrin 21 1.5, and when can generic versions of Loestrin 21 1.5 launch?
Loestrin 21 1.5 is a drug marketed by Teva Branded Pharm and is included in one NDA.
The generic ingredient in LOESTRIN 21 1.5 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
US Patents and Regulatory Information for LOESTRIN 21 1.5
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | LOESTRIN 21 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 017875-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
